Roots Analysis has done a detailed study on Endocannabinoid System Targeted Therapeutics Market, 2020-2030 “ covering key aspects of the industry’s evolution and identifying potential future growth opportunities.
To order this 250+ page report, which features 140+ figures and 170+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/endocannabinoid-therapeutics/316.html
Key Market Insights
For more information, please visit “Endocannabinoid System Targeted Therapeutics Market, 2020-2030.“
Table of Contents
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Neuropharmacology and Working Mechanism of the Endocannabinoid System
3.3. Potential Therapeutic Applications of Cannabinoids
3.4. Legal Aspects and Regulations
3.5. Existing Challenges
3.6. Future of Cannabinoid Therapies
4. MARKET LANDSCAPE: ENDOCANNABINOID SYSTEM TARGETED THERAPEUTICS
4.1. Chapter Overview
4.2. Drugs Targeting Endocannabinoid System: Marketed and Development Pipeline
4.2.1. Analysis by Phase of Development
4.2.2. Analysis by Target Therapeutic Area
4.2.3. Analysis by Route of Administration
4.2.4. Analysis by Dosing Frequency
4.2.5. Analysis by Target Receptor
4.2.6. Grid Analysis: Distribution by Phase of Development, Target Therapeutic Area and Target Receptor
4.3. Endocannabinoid System Targeted Therapeutics: List of Developers
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size and Geographical Location
4.4. List of Cannabis Suppliers
5. COMPANY PROFILES
5.1. Chapter Overview
5.2. GW Pharmaceuticals
5.2.1. Company Overview
5.2.2. Financial Information
5.2.3. Endocannabinoid Targeting Therapeutics Portfolio
5.2.4. Recent Developments and Future Outlook
5.3. Corbus Pharmaceuticals
5.3.1. Company Overview
5.3.2. Endocannabinoid Targeting Therapeutics Portfolio
5.3.3. Recent Developments and Future Outlook
5.4. Tilray
5.4.1. Company Overview
5.4.2. Financial Information
5.4.3. Endocannabinoid Targeting Therapeutics Portfolio
5.4.3.2. Recent Developments and Future Outlook
5.5. Pure Green
5.5.1. Company Overview
5.5.2. Endocannabinoid Targeting Therapeutics Portfolio
5.6. Tetra Bio-Pharma
5.6.1. Company Overview
5.6.2. Endocannabinoid Targeting Therapeutics Portfolio
5.6.3. Recent Developments and Future Outlook
5.7. Botanix Pharmaceuticals
5.7.1. Company Overview
5.7.2. Endocannabinoid Targeting Therapeutics Portfolio
5.7.3. Recent Developments and Future Outlook
5.8. Kalytera Therapeutics
5.8.1. Company Overview
5.8.2. Endocannabinoid Targeting Therapeutics Portfolio
5.8.3. Recent Developments and Future Outlook
5.9. Therapix Biosciences
5.9.1. Company Overview
5.9.2. Endocannabinoid Targeting Therapeutics Portfolio
5.9.3. Recent Developments and Future Outlook
5.10. Zelira Therapeutics
5.10.1. Company Overview
5.10.2. Endocannabinoid Targeting Therapeutics Portfolio
5.10.3. Recent Developments and Future Outlook
5.11. Avicanna
5.11.1. Company Overview
5.11.2. Financial Information
5.11.3. Endocannabinoid Targeting Therapeutics Portfolio
5.11.4. Recent Developments and Future Outlook
5.12. GB Sciences
5.12.1. Company Overview
5.12.2. Financial Information
5.12.3. Endocannabinoid Targeting Therapeutics Portfolio
5.12.4. Recent Developments and Future Outlook
6. ACADEMIC GRANTS ANALYSIS
6.1. Chapter Overview
6.2. Scope and Methodology
6.3. Endocannabinoid System Targeted Therapeutics: List of Grants Awarded by National Institutes of Health (NIH)
6.3.1. Analysis by Year of Grant Award
6.3.2. Analysis by Amount Awarded
6.3.3. Analysis by Administering Institute Center
6.3.4. Analysis by Funding Institute Center
6.3.5. Analysis by Support Period
6.3.6. Analysis by Funding Institute Center and Support Period
6.3.7. Analysis by Type of Grant Application
6.3.8. Analysis by Purpose of Grant Award
6.3.9. Analysis by Grant Mechanism
6.3.10. Word Cloud Analysis: Emerging Focus Areas
6.3.11. Analysis by Study Section Involved
6.3.12. Popular NIH Departments: Analysis by Number of Grants
6.3.13. Analysis by Types of Recipient Organizations
6.3.14. Prominent Program Officers: Analysis by Number of Grants
6.3.15. Popular Recipient Organizations: Analysis by Number of Grants
6.3.16. Regional Analysis of Recipient Organizations
7. PARTNERSHIPS AND COLLABORATIONS
7.1. Chapter Overview
7.2. Partnership Models
7.3. Endocannabinoid Targeted Therapeutics: List of Partnerships and Collaborations
7.3.1. Analysis by Year of Partnership
7.3.2. Analysis by Type of Partnership
7.3.3. Analysis by Type of Partnership and Target Disease Indication
7.3.4. Analysis by Year of Partnership and Type of Partner
7.3.5. Most Active Players: Analysis by Number of Partnerships
7.3.6. Regional Analysis
7.3.7. Intercontinental and Intracontinental Agreements
8. MERGERS AND ACQUISITIONS
8.1. Chapter Overview
8.2. Acquisition M
- Dev Links is offering Custom Website Development in UAE. Our services include but not limited to Logi designing, custom
- centrafrique-le-gouvernement-accuse-l-ex-président-bozizé-de-fomenter-un-coup-d-état
- Roots Analysis has done a detailed study on Patient Recruitment and Retention Services Marker, 2019-2030.
- 100% real and updated exam questions with answers for all famous certifications. Pass in first attempt .Error Free Products with 24/7 Customer Support.Special discount offer for all customer